Open access
Open access
Powered by Google Translator Translator

RCT | In patients with CKD (eGFR 20-45 mL/min per 1.73 m2), Empagliflozin reduced the risk of progression of kidney disease.

7 Nov, 2022 | 12:56h | UTC

Empagliflozin in Patients with Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: EMPA-KIDNEY supports SGLT2 inhibition for chronic kidney disease – medwire News

Video Summary: EMPA-KIDNEY results: Empagliflozin reduces kidney disease progression and cardiovascular deaths

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.